Prognostic Value of Pentraxin-3 Level in Patients with STEMI and Its Relationship with Heart Failure and Markers of Oxidative Stress

Marie Tomandlova, Jiri Jarkovsky, Josef Tomandl, Lenka Kubkova, Petr Kala, Simona Littnerova, Jana Gottwaldova, Petr Kubena, Eva Ganovska, Martin Poloczek, Jindrich Spinar, Christian Mueller, Alexandre Mebazaa, Monika Pavkova Goldbergova, and Jiri Parenica

1. Department of Biochemistry, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
2. Institute of Biostatistics and Analyses, Masaryk University, 625 00 Brno, Czech Republic
3. Department of Cardiovascular Disease, International Clinical Research Center, St. Anne’s University Hospital, 656 91 Brno, Czech Republic
4. Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic
5. Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
6. Department of Biochemistry, University Hospital Brno, 625 00 Brno, Czech Republic
7. Department of Internal Medicine, University Hospital, 4031 Basel, Switzerland
8. Department of Anesthesiology and Critical Care Medicine, Saint Louis Lariboisiére University Hospital, 75475 Paris, France
9. Cardiac Diseases and Biomarkers, INSERM UMR 942, Saint Louis Lariboisiére University Hospital, 75475 Paris, France
10. Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic

Correspondence should be addressed to Jiri Parenica; jiri.parenica@atlas.cz

Received 2 February 2015; Revised 9 March 2015; Accepted 10 March 2015

Academic Editor: Stamatios Theocharis

Copyright © 2015 Marie Tomandlova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Pentraxin-3 (PTX3) appears to have a cardioprotective effect through a positive influence against postreperfusion damage. This study assesses the prognostic value of PTX3 level and its relationship with clinical parameters and markers of oxidative stress and nitric oxide metabolism in patients with ST-elevation myocardial infarction (STEMI). Methods. Plasma/serum levels of several biomarkers of inflammation and oxidative stress and nitrite/nitrate were assessed upon admission and 24 h after STEMI onset in patients treated by primary percutaneous coronary intervention. Results. ROC analysis showed that plasma PTX3 at 24 h was a strong predictor of 30-day and 1-year mortality and independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year. The inflammatory response expressed by PTX3 had a significant relationship with age, heart failure, infarct size, impaired flow in the infarct-related artery, and renal function and positively correlated with neopterin, TNF-α, 8-hydroxy-2′-deoxyguanosine, and nitrite/nitrate. Conclusions. Plasma PTX3 at 24 h after STEMI onset is a strong predictor of 30-day and 1-year mortality. PTX3 as a single biomarker is comparable with currently used scoring systems (TIMI or GRACE) or B-type natriuretic peptide. PTX3 is also an independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year.

1. Introduction

Inflammation has a crucial role during the acute phase and healing process after acute myocardial infarction (MI). The inflammatory response is associated with the production of many mediators. Increased levels of C-reactive protein (CRP) during the MI have been demonstrated to be an independent negative prognostic factor [1, 2]. CRP activates complement via the classical pathway and thereby contributes to the lysis and removal of damaged myocardial cells [3]. An excessively
high inflammatory response as expressed by overproduction of CRP may lead to worsening function and remodeling of the left ventricle [4, 5].

Pentraxin-3 (PTX3), also known as “long pentraxin,” belongs to the evolutionarily conserved pentraxin family, together with CRP. PTX3 seems to have, in comparison with CRP, a different pathophysiological role in patients with MI. PTX3 can bind to component C1q and thus prevent unwanted excessive activation of complement [6]. Binding of PTX3 to P-selectin reduces further neutrophil infiltration into the site of myocardial injury [7], and binding to activated platelets reduces proinflammatory and prothrombotic effects in MI patients [8]. Significantly greater myocardial damage has been demonstrated in ptx3-deficient mice compared with wild-type controls. The protective effect of PTX3 is probably caused by influencing of the postreperfusion damage of myocardial tissue [9].

PTX3 levels in plasma of the patients with MI increase rapidly and reach their peak 6–8 h from symptom onset [10]. Early increase in the plasma concentration of PTX3 in MI patients is associated with neutrophil degranulation [8]. Local production of PTX3 by different cells in affected areas contributes to increased plasma PTX3 concentrations in the late stages of MI [9, 11]. Mononuclear phagocytes, dendritic cells, fibroblasts, and vascular endothelial cells produce PTX3 in response to primary inflammatory signals, which are mainly from cytokines such as interleukin-1β and tumor necrosis factor alpha (TNF-α) [12]. Expression of PTX3 in a model of MI and reperfusion is controlled through nuclear factor-kappa B [13].

Increased PTX3 levels in ST-elevation myocardial infarction (STEMI) patients upon hospital admission have been demonstrated to be independent predictors of 3-month mortality, but not of readmission to hospital for acute heart failure (AHF) [10, 14]. A predictive value in non-ST-elevation myocardial infarction (NSTEMI) patients was not proven [15]. The current risk stratification in STEMI patients based only on basic clinical parameters is limited [16–18].

In the present study, we evaluated the 30-day and one-year prognostic value of PTX3 level in addition to a validated clinical model in consecutive STEMI patients treated by primary percutaneous coronary intervention (PCI), the one-year prognostic value of PTX3 level in addition to clinical model to predict combined end-point of mortality or left ventricle dysfunction, the relationship between PTX3 level and clinical parameters, and the association of plasma PTX3 level with other inflammatory markers, markers of oxidative stress, and markers associated with the metabolism of nitric oxide (NO).

2. Methods

2.1. Study Population. The study cohort was 262 patients with STEMI referred for primary PCI and admitted to the Coronary Care Unit of the Internal Cardiology Department of University Hospital Brno (Brno, Czech Republic). Exclusion criteria were age >80 years, known or newly diagnosed malignancy, inflammatory or connective-tissue disease, disease other than cardiovascular disease that would clearly limit the 1-year prognosis, and noncompliance with treatment. The study protocol complied with the Declaration of Helsinki and was approved by the Ethics Committees of the Faculty Hospital Brno. Written informed consent was obtained from all subjects before participation in the trial. The diagnosis of STEMI was made based on MI symptoms, appropriate electrocardiographic changes, and elevation of levels of troponin I. Time from onset of chest pain to primary PCI was <12 h. Left ventricular end-diastolic pressure (LVEDP) was measured before left ventricular angiography using a fluid-filled catheter (5-F pigtail catheter) with the patient in the supine position before primary PCI. Thrombolysis in myocardial infarction (TIMI) flow grade was assessed before and after primary PCI.

Patients were monitored prospectively in the cardiology outpatient department of University Hospital Brno. One-year mortality was assessed in all patients.

2.2. Echocardiography Assessment. Echocardiography was carried out during the index admission (between the third and fifth day after MI onset) and after one year. Left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), and left ventricular ejection fraction (LVEF) were estimated using the biplanar Simpson’s rule from apical two- and four-chamber views. Echocardiography was assessed by two operators using Vivid 7 or Vivid i (GE Vingmed Ultrasound).

2.3. Laboratory Methods. Venous blood samples were drawn immediately upon hospital admission (median of 3 h from onset of chest pain) and 24 h after onset of MI. Serum and EDTA-plasma samples were aliquoted and stored immediately at −80°C until assay. Standard biochemical and hematological blood tests were done upon hospital admission while other tests were done within one to four months of collection. Plasma levels of troponin I and B-type natriuretic peptide (BNP) were analyzed using the microparticle enzyme immunoassays (AxSYM, Abbott Laboratories, IL, USA). Plasma levels of PTX3 were measured with an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, MN, USA) and plasma levels of TNF-α with an ELISA (Invitrogen, CA, USA). Serum concentrations of neopterin were measured with an ELISA (IBL International, Germany), serum concentrations of 8-hydroxy-2′-deoxyguanosine (8-OHdG) with an ELISA (Cayman Chemicals, MI, USA), and serum concentrations of superoxide dismutase (SOD) with an ELISA kit (Bender MedSystems, Austria). Plasma levels of NO were evaluated by measuring the nitrite/nitrate (NOx) using a colorimetric assay kit based on the Griess reaction (R&D Systems). Ferric-reducing ability of plasma (FRAP) was measured using the method of Benzie and Strain [19] with modifications on the assay on 96-well microplate on a Spectramax 340PC Microplate Reader (Molecular Devices, CA, USA). The plasma level of malondialdehyde (MDA) was assessed by high-performance liquid chromatography (HPLC) with fluorescent detection (Shimadzu 10A series HPLC system, Shimadzu Corp., Japan) after derivation by...
thiobarbituric acid as described by Khoschsorur et al. [20]. Plasma levels of total low-molecular-weight thiols were measured by HPLC with fluorescent detection (Shimadzu) as described by Vester and Rasmussen [21]. The plasma level of vitamin A and vitamin E was measured after extraction by HPLC with UV detection (Shimadzu) [22].

2.4. Statistical Methods. Standard descriptive statistics were applied in the analysis: absolute and relative frequencies for categorical variables and median supplemented by 5th–95th percentile ranges for quantitative variables. The significance of differences among groups was analyzed using the maximum-likelihood chi-square test for categorical variables and Mann-Whitney or Kruskal-Wallis tests for quantitative variables. The relationship between quantitative variables was assessed using the Spearman correlation coefficient. ROC analyses were adopted for the description of the predictive power of variables and identification of optimal cut-off points using Youden’s J statistic. Reclassification analyses (net reclassification improvement (NRI), integrated discrimination improvement (IDI), and category-free net reclassification improvement (cfNRI)) were used for the characterization of improvement of standard TIMI and GRACE risk scores by the addition of new markers and for the comparison of multivariate models with and without PTX3. Analyses were computed using SPSS 22.0.0.1 (IBM Corporation, 2014) and R version 3.1.2 (The R Foundation for Statistical Computing, 2014) with library PredictABEL [23]. The level of significance was set at $\alpha = 0.05$.

3. Results

The comparison of PTX3 levels upon admission and 24 h after onset of MI demonstrated a significant rise of values (0.96 (0.24–4.02) versus 2.13 (0.49–21.64) ng/mL; $P < 0.001$). As the main aim of the study was to evaluate a prognostic value of PTX3, we compared the values of area under the curve (AUC) of ROC analysis for both time points. We found that PTX3 after 24 h had a significantly higher prognostic value than PTX3 upon admission (see below). Based on this result, all following statistical analyses were done with PTX3 after 24 h.

The baseline characteristics of the study cohort divided into tertiles according to plasma PTX3 levels after 24 h are presented in Table 1. Increasing tertiles of PTX3 were associated with older age, diabetes mellitus, increasing LVEDP, and decreased LVEF as shown in Table 1. Moreover, patients with higher values of PTX3 (2nd and 3rd tertiles) had after reperfusion by primary PCI final TIMI flow values of 0 and 1 (i.e., those with an unsuccessful reperfusion above all on microcirculatory level). This association has not been shown to be statistically significant.

The relationship between PTX3 level at 24h and clinical/biochemical parameters as expressed by the Spearman correlation coefficient is shown in Table 5. Univariate analysis revealed the most powerful association of PTX3 level with level of BNP, neopterin, troponin I, NOX, and TNF-α (all at 24 h) and, moreover, with level of BNP, 8-OHdG, glucose, and creatinine upon hospital admission. A negative correlation between PTX3 levels was found with LVEF.

Thirty-day mortality was 0% within the first tertile of PTX3, 1.1% within the second, and 10.5% within the third. One-year mortality was 0% within the first tertile, 4.5% within the second, and 20.9% within the third (Figure 1). We have found a high predictive value of PTX3 level at 24 h for prediction of 30-day and 1-year mortality (AUC 0.873 and 0.835, resp.; both $P < 0.001$; sensitivity 100% and specificity 66%) with optimal cut-off value $> 3.07$ ng/mL. According to the C-statistics, AUC of the previously validated scoring system TIMI for 30-day and 1-year mortality was 0.795 and 0.691 (both $P < 0.001$) for our dataset, respectively, and AUC of GRACE risk score for 30-day and 1-year mortality was 0.841 and 0.783 (both $P < 0.001$), respectively, as shown in Table 6. We also found a high predictive value of BNP level at 24 h for 30-day and 1-year mortality (both AUC 0.812; $P < 0.001$). Addition of PTX3 level at 24 h to TIMI and GRACE risk scores led to nonsignificant improvement of
**Table 1**: Baseline clinical characteristics of patients according to PTX3 level at 24 h after the onset of myocardial infarction.

| Characteristics          | PTX3/24 h tertile |  |  | P value* |
|--------------------------|-------------------|---|---|----------|
|                          | First tertile     | Second tertile | Third tertile |       |
|                          | n = 87            | n = 89          | n = 86         |       |
| Age (years)              | 58.1 (49.0; 75.0) | 63.7 (48.8; 79.7) | 68.5 (53.0; 79.8) | <0.001 |
| Female sex               | 17 (19.5)         | 30 (33.7)       | 30 (34.9)      | 0.041  |
| Systolic BP (mmHg)       | 140 (105; 180)    | 140 (101; 190)  | 140 (85; 180)  | 0.411  |
| Diastolic BP (mmHg)      | 80 (60; 105)      | 79 (55; 105)    | 80 (50; 97)    | 0.278  |
| BMI                      | 28.4 (23.8; 36.4) | 27.7 (22.7; 35.1) | 27.1 (21.1; 34.5) | 0.096  |
| Prior instability        | 33 (37.9)         | 27 (30.3)       | 23 (26.7)      | 0.273  |
| Hypertension             | 53 (60.9)         | 52 (58.4)       | 53 (61.6)      | 0.902  |
| Diabetes mellitus        | 17 (19.5)         | 19 (21.3)       | 32 (37.2)      | 0.016  |
| Dyslipoproteinemia       | 80 (92.0)         | 69 (77.5)       | 71 (82.6)      | 0.023  |
| History of MI            | 8 (9.2)           | 11 (12.4)       | 14 (16.3)      | 0.371  |
| COPD                     | 3 (3.4)           | 6 (6.7)         | 3 (3.5)        | 0.505  |
| ACE inhibitors           | 19 (21.8)         | 26 (29.2)       | 20 (23.3)      | 0.490  |
| Beta blockers            | 18 (20.7)         | 26 (29.2)       | 28 (32.6)      | 0.188  |
| Statins                  | 15 (17.2)         | 19 (21.3)       | 18 (20.9)      | 0.752  |
| ARBs                     | 9 (10.3)          | 3 (3.4)         | 9 (10.5)       | 0.105  |
| Initial TIMI flow        |                   |  |  | 0.055  |
| 0                        | 41 (47.1)         | 58 (65.2)       | 53 (61.6)      |       |
| 1                        | 9 (10.3)          | 13 (14.6)       | 7 (8.1)        |       |
| 2                        | 18 (20.7)         | 7 (7.9)         | 13 (15.1)      |       |
| 3                        | 19 (21.8)         | 11 (12.4)       | 13 (15.1)      |       |
| Final TIMI flow          |                   |  |  | 0.018  |
| 0                        | 0 (0.0)           | 4 (4.5)         | 1 (1.2)        |       |
| 1                        | 0 (0.0)           | 0 (0.0)         | 2 (2.3)        |       |
| 2                        | 4 (4.6)           | 12 (13.5)       | 9 (10.5)       |       |
| 3                        | 83 (95.4)         | 73 (82.0)       | 74 (86.0)      |       |
| LVEDP (mmHg)             | 23 (11; 34)       | 26 (13; 38)     | 27 (13; 40)    | 0.006  |
| LVEF (%)                 | 55 (40; 68)       | 52 (34; 70)     | 45 (25; 62)    | <0.001 |
| Killip                   |                   |  |  | <0.001 |
| I                        | 74 (85.1)         | 70 (78.7)       | 48 (55.8)      |       |
| II                       | 12 (13.8)         | 18 (20.2)       | 23 (26.7)      |       |
| III + IV                 | 1 (1.1)           | 1 (1.1)         | 15 (17.4)      |       |
| Acute heart failure      | 13 (14.9)         | 19 (21.3)       | 38 (44.2)      | <0.001 |
| Acute kidney injury      | 6 (6.9)           | 2 (2.2)         | 12 (14.0)      | 0.011  |
| 30day mortality          | 0 (0.0)           | 1 (1.1)         | 9 (10.5)       | <0.001 |
| 1-year mortality         | 0 (0.0)           | 4 (4.5)         | 18 (20.9)      | <0.001 |

All categorical variables represented as n (%) and continuous variables as median (the 5th; 95th percentiles).

* P values from the Kruskal-Wallis test or χ² maximum-likelihood test (categorical variables).

BP: blood pressure; BMI: body mass index; MI: myocardial infarction; COPD: chronic obstructive pulmonary disease; ACE: angiotensin-converting enzyme; ARBs: antagonists for the type-2 receptor of angiotensin II; TIMI: thrombolysis in myocardial infarction; LVEDP: left ventricular end-diastolic pressure; LVEF: left ventricular ejection fraction; Killip: Killip classification of heart failure.

A prognostic value of the clinical model for prediction of 30-day and 1-year mortality (Table 6). PTX3 upon admission demonstrated significant but moderate prognostic value for prediction of 1-year mortality but not for 30-day mortality. Addition of PTX3 upon admission to TIMI risk score led to improvement of prognostic value as evaluated by the AUC of the C-statistics. Also, addition of PTX3 upon admission to GRACE score led to improvement of prognostic value of GRACE score as evaluated by the AUC of the ROC analyses (Table 6), but there was no significant improvement in risk reclassification according to NRI or IDI, and there was no significant improvement for prediction of 1-year mortality.
Table 2: Comparison of laboratory characteristics of patients divided according to PTX3 level in 24 h after the onset of chest pain.

| Laboratory parametera | PTX3/24 h tertiles | P value* |
|------------------------|---------------------|----------|
|                        | First tertile n = 87 | Second tertile n = 89 | Third tertile n = 86 |
| PTX3 (ng/mL)           | 1.0 (0.3; 1.4)      | 2.1 (1.6; 3.3)      | 6.4 (3.6; 45)       | <0.001 |
| Troponin I (pg/mL)     | 24.3 (1.0; 125)     | 56.3 (4.0; 150)     | 79.9 (4.8; 228)     | <0.001 |
| BNP (pg/mL)            | 191 (57.9; 581)     | 328 (89.0; 845)     | 490 (108.3; 1485)   | <0.001 |
| NOx (μmol/L)           | 23.0 (12.0; 47.0)   | 24.0 (11.0; 59.0)   | 49.0 (20.0; 78.0)   | <0.001 |
| TNF-α (pg/mL)          | 2.1 (0.7; 6.4)      | 2.5 (0.9; 6.8)      | 3.1 (1.4; 8.3)      | 0.009  |
| Neopterin (nmol/L)     | 6.4 (4.2; 12)       | 7.9 (4.9; 21)       | 9.5 (5.7; 27)       | <0.001 |
| MDA (μmol/L)           | 0.5 (0.1; 1.0)      | 0.5 (0.3; 1.1)      | 0.5 (0.1; 0.9)      | 0.153  |
| 8-OHdG (ng/mL)         | 8.5 (4.7; 13)       | 7.6 (5.4; 12)       | 7.9 (4.7; 10)       | 0.311  |
| SOD (ng/mL)            | 66 (26; 204)        | 64 (25; 226)        | 89 (36; 601)        | 0.001  |
| FRAP (μmol/L)          | 876 (520; 1,223)    | 818 (412; 1,197)    | 972 (572; 1,774)    | 0.002  |
| Vitamin A (μmol/L)     | 2.9 (1.5; 4.4)      | 2.6 (1.6; 4.6)      | 2.7 (1.8; 5.2)      | 0.283  |
| Vitamin E (μmol/L)     | 30.5 (17.2; 51.8)   | 30.7 (16.2; 43.8)   | 29.0 (18.0; 45.7)   | 0.670  |

Values are shown as the median (the 5th; 95th percentiles).
*P value based on the Kruskal-Wallis test.
aLaboratory parameters were analyzed 24 h after the onset of chest pain.

PTX3: pentraxin-3; BNP: B-type natriuretic peptide; NOx: nitrite/nitrate; TNF-α: tumor necrosis factor alpha; MDA: malondialdehyde; 8-OHdG: 8-hydroxy-2'-deoxyguanosine; SOD: superoxide dismutase; FRAP: ferric-reducing ability of plasma.

Table 3: Laboratory parameters measured upon admission: the patients were divided according to PTX3 level in 24 h after the onset of chest pain.

| Laboratory parametera | PTX3/24 h tertiles | P value* |
|------------------------|---------------------|----------|
|                        | First tertile n = 87 | Second tertile n = 89 | Third tertile n = 86 |
| Leukocytes             | 11.7 (7.4; 18.1)    | 11.7 (6.6; 18.8)    | 12.9 (7.7; 22.4)    | 0.043  |
| Glycaemia (mmol/L)     | 7.4 (5.3; 16)       | 8.4 (6.1; 13)       | 8.4 (5.8; 20)       | 0.009  |
| Cholesterol (mmol/L)   | 5.5 (3.7; 73)       | 4.9 (3.5; 71)       | 5.2 (3.1; 72)       | 0.015  |
| Triglycerides (mmol/L) | 2.2 (0.8; 6.2)      | 1.6 (0.7; 3.7)      | 1.4 (0.5; 3.8)      | <0.001 |
| HDL (mmol/L)           | 1.2 (0.8; 17)       | 1.2 (0.8; 21)       | 1.5 (0.6; 2.0)      | <0.001 |
| LDL (mmol/L)           | 3.2 (1.7; 4.8)      | 2.7 (1.6; 5.1)      | 3.1 (1.2; 4.6)      | 0.024  |
| Creatinine (μmol/L)    | 83 (59; 119)        | 87 (60; 138)        | 90 (62; 151)        | 0.033  |
| Uric acid (μmol/L)     | 325 (206; 475)      | 303 (180; 488)      | 359 (198; 642)      | 0.013  |
| PTX3 (ng/mL)           | 0.6 (0.2; 2.0)      | 1.0 (0.4; 3.0)      | 1.5 (0.3; 7.9)      | <0.001 |
| BNP (pg/mL)            | 46.1 (15.0; 179)    | 81.8 (15.3; 489)    | 106.3 (15.1; 605)   | <0.001 |
| TNF-α (pg/mL)          | 1.4 (1.1; 37)       | 3.3 (1.9; 4.1)      | 2.9 (1.7; 12)       | 0.399  |
| MDA (μmol/L)           | 0.6 (0.3; 1.4)      | 0.5 (0.3; 1.1)      | 0.6 (0.2; 1.2)      | 0.462  |
| 8-OHdG (ng/mL)         | 71 (4.5; 9.5)       | 73 (4.5; 11)        | 83 (5.2; 14)        | <0.001 |
| FRAP (μmol/L)          | 910 (645; 1,309)    | 828 (467; 1,330)    | 987 (493; 1,589)    | 0.052  |
| Cysteine (μmol/L)      | 260 (192; 326)      | 259 (203; 348)      | 263 (163; 391)      | 0.924  |
| Homocysteine (μmol/L)  | 9.5 (5.6; 16)       | 10.6 (5.5; 18)      | 9.9 (4.0; 20)       | 0.539  |
| Cysteinylglycine (μmol/L) | 41.5 (30.5; 62.1) | 40.2 (29.3; 59.8) | 41.1 (22.3; 58.2) | 0.182  |
| Glutathione (μmol/L)   | 2.2 (1.1; 3.3)      | 2.3 (1.3; 3.3)      | 2.1 (1.0; 3.7)      | 0.402  |

Values are shown as the median (the 5th; 95th percentiles).
*P value based on the Kruskal-Wallis test.
aLaboratory parameters were analyzed upon hospital admission.

HDL: high density lipoprotein; LDL: low density lipoprotein; PTX3: pentraxin-3; BNP: B-type natriuretic peptide; TNF-α: tumor necrosis factor alpha; MDA: malondialdehyde; 8-OHdG: 8-hydroxy-2'-deoxyguanosine; FRAP: ferric-reducing ability of plasma.

There was also an evaluation of the effect of PTX3 levels on the combined end-point of left ventricular dysfunction and mortality at one year. Results of C-statistics (Table 7) demonstrate the predictive ability of PTX3. For comparison, the two most commonly used biomarkers in patients with acute coronary syndrome are also shown, that is, troponin I and BNP.

Moreover, a multivariate model including basic clinical parameters, troponin I and BNP, is presented in Table 8. The maximum troponin levels reveal the extent of myocardial
Table 4: PTX3 levels in selected groups of patients.

| Gender                | PTX3 (ng/mL)   | P value |
|-----------------------|----------------|---------|
| Male                  | 2.05 (0.49; 25.7) | 0.031   |
| Female                | 2.52 (0.53; 19.4) |         |

| Initial TIMI flow    | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| 0                    | 2.28 (0.66; 36.0) |         |
| 1                    | 1.91 (0.58; 15.3) | 0.061   |
| 2                    | 1.67 (0.41; 31.7) |         |
| 3                    | 1.58 (0.53; 6.83) |         |

| Final TIMI flow       | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| 0 + 1                | 3.35 (1.96; 77.2) | <0.001  |
| 2                    | 2.71 (0.99; 36.0) | 0.067   |
| 3                    | 2.07 (0.49; 19.4) |         |

| Killip               | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| I                    | 1.97 (0.44; 8.53) | <0.001  |
| II                   | 2.80 (0.77; 31.7) |         |
| III + IV             | 14.5 (0.93; 125) |         |

| Acute heart failure  | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| no                   | 1.97 (0.44; 8.53) | <0.001  |
| yes                  | 4.04 (0.81; 45.1) |         |

| Acute kidney injury  | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| no                   | 2.10 (0.49; 15.1) | 0.015   |
| yes                  | 3.83 (0.87; 77.2) |         |

| Diabetes mellitus    | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| no                   | 2.02 (0.49; 14.5) | 0.003   |
| yes                  | 2.89 (0.63; 45.2) |         |

| Hypercholesterolemia | PTX3 (ng/mL)   | P value |
|----------------------|----------------|---------|
| no                   | 2.75 (0.82; 37.5) | 0.021   |
| yes                  | 2.05 (0.49; 15.3) |         |

Values are shown as median (the 5th; 95th percentiles).

*P* values from the Kruskal-Wallis test or $\chi^2$ maximum-likelihood test.

TIMI: thrombolysis in myocardial infarction; Killip: Killip classification of heart failure.

necrosis, levels of BNP indicate left ventricular dysfunction. Independent prognostic factors in a multivariate model were, in addition, heart rate and disabilities of all three coronary arteries. According to C-statistics, AUC was 0.866 (95% CI 0.817–0.916; *P* < 0.001). Addition of PTX3 level at 24 h to the previous model led to an increase of AUC to 0.878 (95% CI 0.830–0.925; *P* < 0.001). Reclassification analysis using cfnR and IDI demonstrated that PTX3 led to a significant improvement in the clinical model including BNP and troponin I (Table 8).

4. Discussion

In this study, we reported that PTX3 level determined upon hospital admission (≈3 h after MI onset) was significantly lower compared with that determined 24 h after MI onset. Also, we reported that PTX3 level 24 h after MI onset had greater prognostic value compared with the value upon hospital admission. Setting the time of sampling (24 h after the onset of chest pain) is close to the expected significant rise of PTX3 levels due to MI [9–11]. Moreover, the time of sampling is exactly associated with MI onset and it is the same for all patients.

Increased values of PTX3 were related to several factors: age; AHF and left ventricular overload expressed by several parameters (increased LVEDP, Killip heart failure class, and increased BNP level); extent of infarct size (as expressed by level of troponin I); renal function (in particular its worsening according to the number of patients with acute kidney injury); and impaired flow of infarct-related arteries (as expressed by TIMI flow before and after PCI). Furthermore, the level of PTX3 was slightly correlated with other markers of inflammation (neopterin and TNF-α), marker of nitric oxide synthase activity ($\text{NO}_x$), and markers associated with oxidative stress (SOD, FRAP, and 8-OhdG upon admission).

We found a PTX3 level at 24 h to be a strong predictor of 30-day and 1-year mortality at least as good as previously validated clinical risk scores (GRACE and TIMI) or BNP level at 24 h.

The actual values of PTX3 and BNP upon hospital admission were not significant predictors of short-term mortality and had only a moderate prognostic value for 1-year mortality.
An increase of a prognostic value of TIMI and GRACE risk scores after addition of PTX3 upon hospital admission was not also significant.

For the first time, according to our knowledge, we evaluated the effect of PTX3 levels on the development of a combined end-point of left ventricular dysfunction (EF < 40%) or mortality at one year. Since the combined end-point is not a validated clinical model, we have developed a multivariate model, in which, among others, we involved also the most commonly used biomarkers of acute coronary syndrome, that is, troponin I and BNP. PTX3 added to this model was evaluated as an independent predictor, which, moreover, led to a significant improvement in risk reclassification of patients.

One important factor in the evaluation of biomarkers in MI is setting the time of measurement of biomarkers in a relation to the onset of chest pain. In our opinion it is preferable to specify the time of measurement of biomarkers according to the time from onset of chest pain over the time of admission to the critical care unit. Sampling of PTX3 at two fixed predefined times, upon admission and 24 h after the onset of chest pain, can be considered to be an advantage in comparison with those chosen in previous studies [10, 14].

Our results are consistent with previous works. Increased production of PTX3 due to heart failure and increased physical stress (in our case expressed by the LVEDP value) has been described by Peri et al. [10] when patients with MI had higher PTX3 levels compared with healthy controls. Moreover, a correlation between CRP and PTX3 levels was not found in this group of patients. Latini et al. [14] demonstrated that, in patients with STEMI treated by thrombolysis, the PTX3 level was associated with heart failure and was confirmed as an independent prognostic factor of 3-month mortality. In addition, they found a very weak correlation between PTX3 and CRP levels.

It is known that production of PTX3 may also be influenced by genetic variants. Three common PTX3 polymorphisms (rs2305619, rs3816257, and rs1840680) have been demonstrated to be factors influencing PTX3 levels in patients with MI [24]. Unfortunately, based on performed tests, we could not assess if individuals with higher levels of PTX3 as a result of genetic predisposition had a better prognosis.

Moreover, PTX3 contributes to an inflammatory reaction at the site of infarction and probably should have a cardioprotective effect related to the modulation of activity of dendritic cells and decoupling of the C1q components of complement in the fluid phase [6, 9]. Complement activation alone in MI amplifies damage to the myocardium [25]. Our findings are not in compliance with findings from previous research that supposed protective effect of PTX3. According to our results, increasing concentrations of PTX3 are associated with poor prognosis of patient, that is, with higher risk of mortality and with development of left ventricular dysfunction. Whether the potential prognostic value of PTX3 reflects its influence on coagulation and complement activation or if high levels of PTX3 are a protective response reflecting the degree of

---

**Table 6:** ROC analyses for prediction of 30-day and 1-year mortalities according to the TIMI and GRACE risk scores and levels of PTX3 at 24 h after the onset of myocardial infarction and upon admission.

| Marker                  | AUC (95% CI) 30-day mortality | P value | AUC (95% CI) 1-year mortality | P value |
|-------------------------|-------------------------------|---------|------------------------------|---------|
| TIMI                    | 0.795 (0.741–0.842)           | <0.001  | 0.691 (0.582–0.800)          | <0.001  |
| GRACE                   | 0.841 (0.717–0.966)           | <0.001  | 0.783 (0.672–0.893)          | <0.001  |
| PTX3                    | 0.873 (0.801–0.945)           | <0.001  | 0.835 (0.769–0.900)          | <0.001  |
| BNP                     | 0.812 (0.684–0.941)           | <0.001  | 0.812 (0.715–0.909)          | <0.001  |
| TIMI + PTX3             | 0.847 (0.797–0.888)           | <0.001  | 0.761 (0.669–0.853)          | <0.001  |
| GRACE + PTX3            | 0.851 (0.730–0.972)           | <0.001  | 0.791 (0.682–0.901)          | 0.016   |
| PTX3/adm*               | 0.652 (0.459–0.846)           | 0.143   | 0.663 (0.544–0.782)          | <0.001  |
| BNP/adm*                | 0.664 (0.500–0.828)           | 0.078   | 0.727 (0.605–0.848)          | <0.001  |
| TIMI + PTX3/adm*        | 0.863 (0.815–0.903)           | <0.001  | 0.760 (0.656–0.864)          | <0.001  |
| GRACE + PTX3/adm*       | 0.891 (0.759–1.000)           | <0.001  | 0.833 (0.728–0.939)          | <0.001  |

*PTX3 or BNP at time of admission.

AUC: area under curve; CI: confidence interval; TIMI: thrombolysis in myocardial infarction (risk score); GRACE: global registry of acute coronary events (risk score); PTX3: pentraxin-3 at 24 h after onset of myocardial infarction; BNP: B-type natriuretic peptide at 24 h after onset of myocardial infarction.

**Table 7:** Predictive power and optimal cut-offs of biomarkers for the prediction of combined endpoint (mortality or EF ≤40% at one year).

| Predictors          | AUC (95% CI) | P value | Cut-off* | Sensitivity | Specificity |
|---------------------|--------------|---------|----------|-------------|-------------|
| PTX3                | 0.756 (0.675; 0.837) | <0.001  | >2.1     | 0.864       | 0.572       |
| Troponin I (max)    | 0.705 (0.610; 0.801) | <0.001  | >90      | 0.568       | 0.826       |
| BNP                 | 0.800 (0.731; 0.870) | <0.001  | >500     | 0.636       | 0.827       |

* Values in ng/mL (PTX3) and pg/mL (troponin I, BNP).

AUC: area under curve; CI: confidence interval; PTX3: pentraxin-3 at 24 h after onset of myocardial infarction; BNP: B-type natriuretic peptide at 24 h after onset of myocardial infarction.
Table 8: Predictors of combined end-point (mortality or EF <40% at one year).

| Predictors                  | Univariate |       |       | Multivariate without PTX3 |       |       | Multivariate with PTX3 |       |
|-----------------------------|------------|-------|-------|---------------------------|-------|-------|------------------------|-------|
|                             | OR (95% CI)| P value* |       | OR (95% CI)               | P value* | OR (95% CI) | OR (95% CI)         | P value* |
| PTX3 >2.1 ng/mL             | 8.304 (3.364; 20.498) | **<0.001** |       | 4.329 (1.966; 9.531) | **<0.001** | 3.700 (1.332; 10.279) | **0.012** |
| Troponin I (max) >90 pg/mL  | 6.241 (3.102; 12.556) | **<0.001** |       | 4.329 (1.966; 9.531) | **<0.001** | 3.321 (1.461; 7.549) | **0.004** |
| BNP >500 pg/mL              | 8.361 (4.104; 17.033) | **<0.001** |       | 6.777 (3.068; 14.970) | **<0.001** | 4.990 (2.196; 11.340) | **<0.001** |
| Women                       | 1.125 (0.558; 2.267) | 0.743 |       |                           |         |       |                       |         |
| Age                         | 1.035 (0.998; 1.072) | 0.063 |       |                           |         |       |                       |         |
| BMI                         | 1.057 (0.980; 1.140) | 0.151 |       |                           |         |       |                       |         |
| Systolic BP                 | 0.991 (0.979; 1.003) | 0.158 |       |                           |         |       |                       |         |
| Heart rate                  | 1.027 (1.008; 1.046) | **0.005** | 1.029 (1.007; 1.052) | **0.009** | 1.030 (1.008; 1.054) | **0.008** |
| Glycaemia at entry          | 1.124 (1.044; 1.211) |       |       |                           |         |       |                       |         |
| Creatinine at entry         | 1.024 (1.011; 1.037) |       |       |                           |         |       |                       |         |
| Diabetes mellitus           | 3.019 (1.531; 5.952) |       |       |                           |         |       |                       |         |
| Hypertension                | 2.644 (1.241; 5.634) |       |       |                           |         |       |                       |         |
| Dyslipoproteinemia           | 1.033 (0.425; 2.509) |       |       |                           |         |       |                       |         |
| History of MI/PCI/CABG      | 2.745 (1.253; 6.013) |       |       |                           |         |       |                       |         |
| Pain onset-balloon time     | 0.994 (0.976; 1.013) |       |       |                           |         |       |                       |         |
| IRA-LAD/left main diseases  | 2.090 (1.079; 4.050) |       |       |                           |         |       |                       |         |
| Three vessels diseases      | 2.183 (1.408; 3.383) | **<0.001** |       | 2.079 (1.230; 3.514) | **0.006** | 1.985 (1.159; 3.398) | **0.012** |
| cNRI                        | Reclassification analysis computed for multivariate model containing PTX3 against model without PTX3 | 0.882 (0.637; 1.126) | **<0.001** | 0.028 (0.006; 0.051) | **0.014** |
| IDI                         | Reclassification analysis computed for multivariate model containing PTX3 against model without PTX3 | 0.882 (0.637; 1.126) | **<0.001** | 0.028 (0.006; 0.051) | **0.014** |

*Based on logistic regression.

PTX3: pentraxin-3 at 24 h after onset of myocardial infarction; BNP: B-type natriuretic peptide at 24 h after onset of myocardial infarction; BMI: body mass index; BP: blood pressure; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; IRA: infarct related artery; LAD: left anterior descending.

Inflammation and myocardial injury is not fully understood [26].

Our data support previous findings that an extensive inflammatory response plays an important adverse role in acute phase of MI [27, 28]. Recently published work in patients with NSTEMI demonstrated that inhibition of the p38 mitogen-activated protein kinase (p38MAPK) (a nexus point in inflammation, sensing and stimulating cytokine production, and driving cell migration and death) by new drug losmapimod decreases inflammatory response expressed by high sensitivity CRP at 72 h. At the same time the treatment led to significant decrease of BNP at 12 weeks [29]. Inflammatory reactions at the infarct site are associated with increased production of neopterin by macrophages after stimulation by interferon-γ [30]. Higher levels of neopterin are associated with development of left ventricular dysfunction [31] and left ventricular remodelling [32] in patients with STEMI. TNF-α is rapidly released from resident mast cells and macrophages during MI [33] and its level is correlated closely with the extent of MI [34]. Our results showed a significant association between tertiles of PTX3 levels and those of neopterin and TNF-α and also significant but weak correlation between PTX3 at 24 h and level of neopterin and TNF-α in whole group of patients.

In this paper we demonstrate for the first time that increased levels of PTX3 in MI patients are significantly associated with higher levels of NOx, stable products of nitric oxide metabolism. The activity of inducible NO synthase is particularly interesting; the high levels of NO could lead to the worsening of left ventricular function, vasodilatation, and progression of hypotension [35].

Myocardial ischemia and subsequent reperfusion lead to increased production of reactive oxygen species (ROS) [36]. The toxic effects of ROS lead to damage to all cells components, including DNA, lipids, and proteins. Determination of individual ROS is very difficult, and their amount is assessed through appropriate markers. A marker of oxidative damage to DNA is 8-OHdG. In our study we found a weak significant correlation between levels of 8-OHdG upon hospital admission and PTX3 concentration 24 h after MI onset. Previously reported studies have shown that increased serum levels of 8-OHdG in patients with MI correspond with...
the severity of heart failure and left ventricular dysfunction [37, 38]. On the other hand, in case of MDA, another marker of oxidative stress, no significant correlation with levels of PTX3 was found.

We also evaluated the association between PTX3 and total antioxidant capacity of plasma, which was determined by the FRAP assay. We found a weak positive correlation between levels of PTX3 and FRAP. However, FRAP includes among others a considerable contribution of uric acid, a potent antioxidant, whose levels are elevated in MI [39]. The concentrations of uric acid within tertiles of PTX3 showed the same tendency as FRAP (Table 3). Contrary to our results, the relationship between PTX3 level and compounds with antioxidant activity was demonstrated by Hill and colleagues [40] who found that endothelial cells produced lower levels of PTX3 if incubated in vitro with addition of antioxidant substances (N-acetylcysteine, trolox, and idebenone).

The increase in the total antioxidant capacity of plasma may be caused by the release of intracellular antioxidants into the bloodstream as a result of the lysis of erythrocytes and epithelium after MI [41]. We found a weak significant correlation between levels of PTX3 and SOD. SOD is free radical-scavenging enzyme and is one of the first lines of “cellular defence” against oxidative injury. The increase in SOD level was presumably due to damage of myocardial tissue during MI [42]. We did not find a significant correlation between PTX3 level and antioxidant vitamins (A and E) and thiols.

There are limitations to this study. First, the study cohort could be considered relatively limited; on the other hand we evaluated an extensive list of new blood-based biomarkers. Second, the study was carried out at a single centre. Nevertheless, we studied a homogenous group of STEMI patients with a precisely documented number of unique invasive parameters (LVEDP, TIMI flow of infarct-related arteries) before and after primary PCI. Third, evaluation of PTX3 level assessed at the time of supposed peak value is interesting. However, we consider that assessment of some prognostic biomarkers 24 h after the onset of chest pain is, from a prognostic viewpoint, more practical and this approach would allow comparison of the results of different studies.

5. Conclusions

We demonstrated that PTX3 levels assessed 24 h after MI onset were strong and sensitive predictors of 30-day and 1-year mortality and could be used to identify high-risk patients requiring increased care. According to our results, prognostic value of PTX3 as a single biomarker is at least as good as currently used TIMI or GRACE risk scoring systems or other powerful predictors like BNP. Increased level of PTX3 is also an independent predictor of combined end-point of left ventricle dysfunction or mortality at one year.

Abbreviations

AHF: Acute heart failure
AUC: Area under the curve
BNP: B-type natriuretic peptide
cfNRI: Category-free net reclassification improvement
CRP: C-reactive protein
FRAP: Ferric-reducing ability of plasma
GRACE: Global registry of acute coronary events
8-OhdG: 8-Hydroxy-2’-deoxyguanosine
IDI: Integrated discrimination improvement
LVEDP: Left ventricular end-diastolic pressure
LVEDV: Left ventricular end-diastolic volume
LVEF: Left ventricular ejection fraction
LVESV: Left ventricular end-systolic volume
MDA: Malondialdehyde
MI: Myocardial infarction
p38MAPK: p38 mitogen-activated protein kinase
NO: Nitric oxide
NO: Nitric oxide
NRI: Net reclassification improvement
NSTE MI: Non-ST-elevation myocardial infarction
PCR: Percutaneous coronary intervention
PTX3: Pentraxin-3
ROS: Reactive oxygen species
SOD: Superoxide dismutase
STEMI: ST-elevation myocardial infarction
TIMI: Thrombolysis in myocardial infarction
TNF-α: Tumor necrosis factor alpha.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by the Project of Conceptual Development of Research Organization (Department of Health) 65269705, Grants MUNI/A/1012 and 0954/2013, and by the European Regional Development Fund, Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123).

References

[1] C. Mueller, H. J. Buettner, J. M. Hodgson et al., “Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients,” Circulation, vol. 103, no. 12, pp. 1412–1415, 2002.
[2] E. Schiele, N. Meneveau, M. F. Seronde et al., “C-reactive protein improves risk prediction in patients with acute coronary syndromes,” European Heart Journal, vol. 31, no. 3, pp. 290–297, 2010.
[3] W. K. Lagrand, H. W. M. Niessen, G. J. Wolbink et al., “C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction,” Circulation, vol. 95, no. 1, pp. 97–103, 1997.
[4] T. Takahashi, T. Anzai, H. Kaneko et al., “Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 299, no. 6, pp. H1795–H1804, 2010.
[5] T. Takahashi, T. Anzai, T. Yoshikawa et al., “Serum C-reactive protein elevation in left ventricular remodeling after acute
myocardial infarction—role of neurohormones and cytokines,” *International Journal of Cardiology*, vol. 88, no. 2-3, pp. 257–265, 2003.

[6] A. J. Nauta, B. Bottazzi, A. Mantovani et al., “Biochemical and functional characterization of the interaction between pentraxin 3 and C1q,” *European Journal of Immunology*, vol. 33, no. 2, pp. 465–473, 2003.

[7] L. Deban, R. C. Russo, M. Sironi et al., “Regulation of leukocyte recruitment by the long pentraxin PTX3,” *Nature Immunology*, vol. II, no. 4, pp. 328–334, 2010.

[8] N. Maugeri, P. Rovere-Querini, M. Slavich et al., “Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction,” *Journal of Immunology*, vol. 187, no. 2, pp. 970–979, 2011.

[9] M. Salio, S. Chimenti, N. de Angelis et al., “Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction,” *Circulation*, vol. 117, no. 8, pp. 1055–1064, 2008.

[10] G. Peri, M. Introna, D. Corradi et al., “PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans,” *Circulation*, vol. 102, no. 6, pp. 636–641, 2000.

[11] M. Nebuloni, F. Pasqualini, P. Zerbi et al., “PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis,” *Cardiovascular Pathology*, vol. 20, no. 1, pp. e27–e35, 2011.

[12] C. Garlanda, B. Bottazzi, A. Bastone, and A. Mantovani, “Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility,” *Annual Review of Immunology*, vol. 23, pp. 337–366, 2005.

[13] A. Basile, A. Sica, E. D’Aniello et al., “Characterization of the promoter for the human long pentraxin PTX3: role of NF-κB in tumor necrosis factor-α and interleukin-1β regulation,” *The Journal of Biological Chemistry*, vol. 272, no. 13, pp. 8172–8178, 1997.

[14] R. Latini, A. P. Maggioni, G. Peri et al., “Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction,” *Circulation*, vol. 110, no. 16, pp. 2349–2354, 2004.

[15] K. M. Eggers, P. W. Armstrong, R. M. Califf et al., “Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome,” *Clinical Biochemistry*, vol. 46, no. 16-17, pp. 1655–1659, 2013.

[16] K. A. Eagle, M. J. Lim, O. H. Dabbous et al., “A validated national registry,” *International Journal of Cardiology*, vol. 111, no. 2, pp. 2727–2733, 2004.

[17] D. A. Morrow, E. M. Antman, A. Charlesworth et al., “TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation—an intravenous nPA for treatment of infarcting myocardium early II trial substudy,” *Circulation*, vol. 102, no. 17, pp. 2031–2037, 2000.

[18] C. Mueller, “Biomarkers and ST-elevation myocardial infarction,” *Heart*, vol. 99, no. 16, 2013.

[19] I. F. F. Benzie and J. J. Strain, “Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration,” *Methods in Enzymology: Oxidants and Antioxidants Part A*, vol. 299, pp. 15–27, 1999.

[20] G. A. Khoschsorur, B. M. Winkhofer-Roob, H. Rabl, T. Auer, Z. Peng, and R. J. Schaur, “Evaluation of a sensitive HPLC method for the determination of malondialdehyde, and application of the method to different biological materials,” *Chromatographia*, vol. 52, no. 3-4, pp. 181–184, 2000.

[21] B. Vester and K. Rasmussen, “High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum,” *European Journal of Clinical Chemistry and Clinical Biochemistry*, vol. 29, no. 9, pp. 549–554, 1991.

[22] W. J. Driskell, J. W. Neese, C. B. Bryant, and M. M. Bashor, “Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography,” *Journal of Chromatography*, vol. 231, no. 2, pp. 439–444, 1982.

[23] S. Kundra, Y. S. Aulchenko, C. M. Van Duijn, and A. C. J. W. Janssens, “PredictABEL: an R package for the assessment of risk prediction models,” *European Journal of Epidemiology*, vol. 26, no. 4, pp. 261–264, 2011.

[24] E. Barbati, C. Specchia, M. Villella et al., “Influence of pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels,” *PLoS ONE*, vol. 7, no. 12, Article ID e53030, 2012.

[25] H. F. Weisman, T. Bartow, M. K. Leppo et al., “Soluble human complement receptor type 1—in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis,” *Science*, vol. 249, no. 4965, pp. 146–151, 1990.

[26] P. Kunes, Z. Holubcova, M. Kolackova, and J. Krejsek, “Pentraxin 3(PTX3): an endogenous modulator of the inflammatory response,” *Mediators of Inflammation*, vol. 2012, Article ID 920517, 10 pages, 2012.

[27] T. Anzai, T. Yoshikawa, H. Shiraki et al., “C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction,” *Circulation*, vol. 96, no. 3, pp. 778–784, 1997.

[28] B. M. Scirica, D. A. Morrow, C. P. Cannon et al., “Clinical application of C-reactive protein across the spectrum of acute coronary syndromes,” *Clinical Chemistry*, vol. 53, no. 10, pp. 1800–1807, 2007.

[29] L. K. Newby, M. S. Marber, C. Melloni et al., “Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial,” *The Lancet*, vol. 384, no. 9949, pp. 1187–1195, 2014.

[30] C. Huber, J. R. Batchelor, D. Fuchs et al., “Immune response-associated production of neopterin—release from macrophages primarily under control of interferon-gamma,” *Journal of Experimental Medicine*, vol. 160, no. 1, pp. 310–316, 1984.

[31] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and M. Garcia-Gonzalez, “Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction,” *International Journal of Cardiology*, vol. 111, no. 2, pp. 318–320, 2006.

[32] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, P. Avanzas, I. Laynez-Cerdeña, and J. C. Kaski, “Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention,” *Atherosclerosis*, vol. 211, no. 2, pp. 574–578, 2010.

[33] S. Gilles, S. Zahler, U. Welsch, C. P. Sommerhoff, and B. F. Becker, “Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers,” *Cardiovascular Research*, vol. 60, no. 3, pp. 608–616, 2003.

[34] E. S. Kehmeier, W. Lepper, M. Kropp et al., “TNF-α, myocardial perfusion and function in patients with ST-segment elevation
myocardial infarction and primary percutaneous coronary intervention,” *Clinical Research in Cardiology*, vol. 101, no. 10, pp. 815–827, 2012.

[35] J. S. Hochman, “Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm,” *Circulation*, vol. 107, no. 24, pp. 2998–3002, 2003.

[36] J. P. Monassier, “Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: basic considerations,” *Archives of Cardiovascular Diseases*, vol. 101, no. 7-8, pp. 491–500, 2008.

[37] R. A. Najar, S. M. H. Ghaderian, H. Vakili et al., “The role of p53, bax, bcl2, and 8-OHdG in human acute myocardial infarction,” *Central European Journal of Biology*, vol. 5, no. 4, pp. 439–445, 2010.

[38] H. Inafuku, Y. Kuniyoshi, S. Yamashiro et al., “Determination of oxidative stress and cardiac dysfunction after ischemia/reperfusion injury in isolated rat hearts,” *Annals of Thoracic and Cardiovascular Surgery*, vol. 19, no. 3, pp. 186–194, 2013.

[39] C. Lazzeri, S. Valente, M. Chiostri, A. Sori, P. Bernardo, and G. F. Gensini, “Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers. A single center experience,” *International Journal of Cardiology*, vol. 138, no. 2, pp. 206–209, 2010.

[40] A. L. Hill, D. A. Lowes, N. R. Webster, C. C. Sheth, N. A. R. Gow, and H. F. Galley, “Regulation of pentraxin-3 by antioxidants,” *British Journal of Anaesthesia*, vol. 103, no. 6, pp. 833–839, 2009.

[41] D. Simić, J. Mimić-Oka, M. Pljesa et al., “Time course erythrocyte antioxidant activity in patients treated by thrombolysis for acute myocardial infarction,” *Japanese Heart Journal*, vol. 44, no. 6, pp. 823–832, 2003.

[42] M. D. Bagatini, C. C. Martins, V. Battisti et al., “Oxidative stress versus antioxidant defenses in patients with acute myocardial infarction,” *Heart and Vessels*, vol. 26, no. 1, pp. 55–63, 2011.